BeiGene, Ltd. (SHA:688235)

Market Cap	181.32B
Revenue (ttm)	30.30B
Net Income (ttm)	-2.85B
Shares Out	n/a
EPS (ttm)	-26.87
PE Ratio	n/a
Forward PE	74.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,561,163
Average Volume	2,456,641
Open	230.00
Previous Close	221.50
Day's Range	226.04 - 234.89
52-Week Range	111.22 - 262.64
Beta	0.49
RSI	47.42
Earnings Date	May 14, 2025

About BeiGene

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688235

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD